STOCK TITAN

Vanguard disaggregates holdings; reports 0 shares of Enanta (ENTA)

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
SCHEDULE 13G/A

Rhea-AI Filing Summary

Enanta Pharmaceuticals Inc — The Vanguard Group filed an amended Schedule 13G reporting 0 shares beneficially owned of Common Stock, representing 0%, following an internal realignment.

The amendment states that on January 12, 2026 The Vanguard Group, Inc. reorganized and certain subsidiaries or business divisions will report beneficial ownership separately in reliance on SEC Release No. 34-39538. The filing is signed by Ashley Grim, Head of Global Fund Administration, dated 03/26/2026.

Positive

  • None.

Negative

  • None.

Insights

Vanguard disaggregated ownership; no remaining beneficial stake in ENTA reported.

The amendment records 0 shares and 0% beneficial ownership as of the filing, attributing the change to an internal realignment on January 12, 2026. It cites SEC Release No. 34-39538 as the basis for separate reporting by subsidiaries.

Cash‑flow treatment and any prior holdings are not stated in the excerpt; subsequent filings would show if any subsidiary reports nonzero holdings. The practical impact depends on whether any Vanguard subsidiary now reports holdings separately.






Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Rule 13d-1(b)
Rule 13d-1(c)
Rule 13d-1(d)




schemaVersion:


SCHEDULE 13G




Comment for Type of Reporting Person: On January 12, 2026, The Vanguard Group, Inc. went through an internal realignment. In accordance with SEC Release No. 34-39538 (January 12, 1998), certain subsidiaries or business divisions of subsidiaries of The Vanguard Group, Inc., that formerly had, or were deemed to have, beneficial ownership with The Vanguard Group, Inc., will report beneficial ownership separately (on a disaggregated basis) from The Vanguard Group, Inc. in reliance on such release. These subsidiaries and/or business divisions pursue the same investment strategies as previously pursued by The Vanguard Group, Inc. prior to the realignment. Further in accordance with SEC Release No. 34-39538 (January 12, 1998), The Vanguard Group, Inc. no longer has, or is deemed to have, beneficial ownership over securities beneficially owned by such subsidiaries and/or business divisions.


SCHEDULE 13G



The Vanguard Group
Signature:Ashley Grim
Name/Title:Head of Global Fund Administration
Date:03/26/2026

FAQ

What does The Vanguard Group report for ENTA ownership?

The Vanguard Group reports 0 shares beneficially owned of Enanta common stock, representing 0%. The amendment attributes this to an internal realignment effective January 12, 2026 and separate reporting by subsidiaries.

Why did Vanguard change its reporting for ENTA?

Vanguard underwent an internal realignment on January 12, 2026, causing certain subsidiaries to report ownership separately. The filing cites SEC Release No. 34-39538 as the regulatory basis for disaggregation.

Does this filing show Vanguard sold ENTA shares?

No sale is stated; the filing reports disaggregated reporting and 0 shares beneficially owned. It does not describe transactions, proceeds, or sales in the provided excerpt.

Who signed the Schedule 13G/A for Vanguard?

The form is signed by Ashley Grim, titled Head of Global Fund Administration, with the signature date shown as 03/26/2026 on the amendment.

Does the amendment identify any subsidiary holdings of ENTA?

The amendment states subsidiaries will report separately under SEC Release No. 34-39538, but the provided excerpt does not list any subsidiary holdings or share counts.
Enanta Pharmaceuticals Inc

NASDAQ:ENTA

View ENTA Stock Overview

ENTA Rankings

ENTA Latest News

ENTA Latest SEC Filings

ENTA Stock Data

363.03M
27.61M
Biotechnology
Pharmaceutical Preparations
Link
United States
WATERTOWN